COLLHealthcare · Drug Manufacturers - Specialty & GenericThe 8 Wall Street analysts covering Collegium Pharmaceutical, Inc. hold a median 12-month price target of $49 — +121.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 6 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Collegium Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (17): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on COLL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +121.2% from it.
Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | $50 |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | — |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | $45 |
| 9 Sept 2026 | Truist Securities | Maintains | Buy | $58 → $49 |
| 9 Sept 2026 | Truist Securities | Maintains | Buy | — |
| 19 Aug 2026 | Barclays | Maintains | Overweight | $56 → $48 |
| 19 Aug 2026 | Barclays | Maintains | Overweight | — |
| 7 Aug 2026 | Piper Sandler | Reiterates | Neutral | — |
| 7 Aug 2026 | Piper Sandler | Reiterates | Neutral | $45 → $43 |
| 6 Aug 2026 | Needham | Maintains | Buy | $56 → $46 |
| 6 Aug 2026 | Needham | Maintains | Buy | — |
| 20 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $60 |
| 20 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2026 | Needham | Reiterates | Buy | $54 → $56 |
| 19 Mar 2026 | Needham | Reiterates | Buy | — |
| 26 Feb 2026 | Needham | Maintains | Buy | — |
| 9 Jan 2026 | Barclays | Maintains | Overweight | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Jan 2026 | Needham | Maintains | Buy | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COLL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, Collegium Pharmaceutical, Inc. returned −34.3% against +17.7% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 41% of US stocks
Cheaper than 71% of US stocks
Cheaper than 40% of US stocks
Cheaper than 54% of US stocks
Higher than 42% of US stocks
Higher than 43% of US stocks
Higher than 68% of US stocks
Higher than 56% of US stocks
Higher than 62% of US stocks
Higher than 78% of US stocks
Higher than 80% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Collegium Pharmaceutical, Inc. has a market value of $678.0M and an enterprise value of $1.8B.
Revenue in the twelve months to 30 June 2026: $808.2M. The latest quarter grew 6.3% year on year.
Net income over the same four quarters: $47.9M, a 5.9% net margin.
Diluted earnings per share, trailing twelve months: $1.24.
Free cash flow in the twelve months to 30 June 2026: $328.3M.
Trailing P/E: 17.2×; forward P/E: 3.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Collegium Pharmaceutical, Inc. employs 423 people — $1.9M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Collegium Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research reported that Collegium Pharmaceutical (COLL) was added to its Zacks Rank #5 (Strong Sell) List on October 7, 2026, along with ARDX and LUV.
Why it matters — The item notes a change in Zacks' rating classification for COLL.
Collegium Pharmaceutical launched Start Talking ADHD, an online resource hub with practical guides for people living with ADHD and the families who support them.
Why it matters — The launch adds an ADHD-focused support resource to Collegium’s offerings, relevant to watchers tracking the company’s activities and outreach.
Seeking Alpha published the transcript of Collegium Pharmaceutical, Inc. (COLL) presenting at the Morgan Stanley 24th Annual Global Healthcare Conference. The item consists of the transcript of the company's presentation at the conference.
Why it matters — A COLL watcher would gain insight into the company's presentation to investors at a major healthcare conference.
Collegium Pharmaceutical announced that its management will participate in several upcoming investor conferences. The company, which focuses on improving the lives of people living with serious and often misunderstood conditions, made the announcement on September 8, 2026.
Why it matters — COLL watchers would care because management's participation in investor conferences signals ongoing investor engagement and potential visibility for the company.
Collegium Pharmaceutical announced it entered into an Accelerated Share Repurchase agreement with Jefferies LLC to repurchase $50 million of its common stock, as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Following completion, $100 million will remain under the program.
Why it matters — The buyback signals the company's ongoing capital-return activity under its authorized repurchase program, which may be of interest to stockholders tracking share count and capital allocation.
The 8 Wall Street analysts covering Collegium Pharmaceutical, Inc. have a median 12-month price target of $49, with estimates ranging from $43 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Collegium Pharmaceutical, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Collegium Pharmaceutical, Inc. 70 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Collegium Pharmaceutical, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +121.2% from the last close, and Ticker Nerd's factor model ranks Collegium Pharmaceutical, Inc. 70 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Collegium Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COLL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $60 over the next 12 months.
Collegium Pharmaceutical, Inc. returned -34.3% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Collegium Pharmaceutical, Inc. is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and attention-deficit/hyperactivity disorder (ADHD).
The most recent item we track (Zacks Investment Research, 7 Oct 2026): "New Strong Sell Stocks for October 7th". Zacks Investment Research reported that Collegium Pharmaceutical (COLL) was added to its Zacks Rank #5 (Strong Sell) List on October 7, 2026, along with ARDX and LUV.
Collegium Pharmaceutical, Inc. is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and attention-deficit/hyperactivity disorder (ADHD). Its current portfolio includes branded prescription products such as Xtampza ER, Belbuca, the Nucynta franchise, Jornay PM, and Symproic, serving patients with complex and chronic medical conditions. The company emphasizes differentiated drug-delivery technology and responsible pain-management therapies, with its business centered on the U.S. market. Collegium Pharmaceutical, Inc. also supports its products through commercial operations, market access, and patient support activities, making it a notable participant in branded specialty pharmaceuticals.
CEO Mr. Vikram Karnani · 423 employees · United States · https://www.collegiumpharma.com
